2022
DOI: 10.1016/j.diabres.2022.109736
|View full text |Cite
|
Sign up to set email alerts
|

IDF21-0368 Metformin and blood cell count (BCC) abnormalities

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 0 publications
0
0
0
Order By: Relevance
“…In these diseases, metformin corrects the previously increased number of leukocytes, especially in the group of neutrophils, and the effect is considered secondary to its ability to reduce abnormal activation of neutrophils and their adherence to the endothelium (8). Nevertheless, in chronic long-term use for diabetes, treatment with metformin was not associated with significant blood cell count abnormalities (12,13).…”
mentioning
confidence: 99%
“…In these diseases, metformin corrects the previously increased number of leukocytes, especially in the group of neutrophils, and the effect is considered secondary to its ability to reduce abnormal activation of neutrophils and their adherence to the endothelium (8). Nevertheless, in chronic long-term use for diabetes, treatment with metformin was not associated with significant blood cell count abnormalities (12,13).…”
mentioning
confidence: 99%